Gilead Sciences Inc. (GILD)
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio.
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
Gilead said the deal would bolster its growing inflammation portfolio.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) reached $146.63 at the closing of the latest trading day, reflecting a +1.88% change compared to its last close.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.
